With the advent of KRAS-targeted drugs, including sotorasib, and RET-targeted, pralsetinib (Thein et al., 2021), version 5.2021 of the NCCN guidelines for NSCLC has been amended to indicate the need for KRAS genetic testing. Here, RET is linked to non-small cell lung carcinoma.